F-Star Therapeutics Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
88
- Latest Deal Type
-
M&A
- (Announced)
- Investors
-
1
F-Star Therapeutics General Information
Description
Developer of tetravalent bispecific antibodies and immunotherapies designed to support immune modulation in cancer treatment. The company offers patent-protected antibody platforms with dual-targeting capability, enabling individuals with cancer to receive extended treatment benefits and improved disease management.
Contact Information
Website
www.f-star.com(Operating Subsidiary)
Corporate Office
- Eddeva B920
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Corporate Office
- Eddeva B920
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
F-Star Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 02-Apr-2025 | Announced | Generating Revenue | |||
| 13. Merger/Acquisition | 08-Mar-2023 | Completed | Clinical Trials - General | |||
| 12. Debt Repayment | 01-Mar-2022 | Completed | Clinical Trials - General | |||
| 11. Reverse Merger | 20-Nov-2020 | Completed | Clinical Trials - General | |||
| 10. Merger/Acquisition | 28-Oct-2014 | Cancelled | Clinical Trials - General | |||
| 9. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
| 8. Later Stage VC | Completed | Startup | ||||
| 7. Later Stage VC | 23-Oct-2013 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC | 13-Apr-2011 | $21.3M | $49.7M | Completed | Clinical Trials - General | |
| 5. Later Stage VC (Series A) | 06-Jan-2010 | $24.5M | $28.4M | Completed | Startup |
F-Star Therapeutics Comparisons
Industry
Financing
Details
F-Star Therapeutics Competitors (52)
One of F-Star Therapeutics’s 52 competitors is Agios Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Achaogen | Formerly VC-backed | South San Francisco, CA | ||||
| Biosynthema | Corporate Backed or Acquired | Saint Louis, MO | ||||
| Oncorus | Formerly VC-backed | Andover, MA |
F-Star Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
F-Star Therapeutics Patents
F-Star Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202304278-D0 | Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy | Inactive | 23-Mar-2023 | ||
| CA-3208653-A1 | Multispecific anti-tcr delta variable 1 antibodies | Pending | 17-Feb-2022 | ||
| AU-2022222299-A1 | Multispecific anti-tcr delta variable 1 antibodies | Pending | 17-Feb-2021 | ||
| EP-4294529-A1 | Multispecific anti-tcr delta variable 1 antibodies | Pending | 17-Feb-2021 | ||
| US-20240132599-A1 | Multispecific anti-tcr delta variable 1 antibodies | Pending | 17-Feb-2021 | C07K16/2863 |
F-Star Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
F-Star Therapeutics Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aescap Life Sciences | Mutual Fund | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| INiTS Universitäres Gründerservice | Accelerator/Incubator | Minority | ||
| M Ventures | Corporate Venture Capital | Minority | ||
| MP Healthcare Venture Management | Corporate Venture Capital | Minority |
F-Star Therapeutics Acquisitions (1)
F-Star Therapeutics’s most recent deal was a Merger/Acquisition with Spring Bank Pharmaceuticals. The deal was made on 20-Nov-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Spring Bank Pharmaceuticals | 20-Nov-2024 | Merger/Acquisition | Discovery Tools (Healthcare) |
F-Star Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
F-Star Therapeutics FAQs
-
When was F-Star Therapeutics founded?
F-Star Therapeutics was founded in 2002.
-
Where is F-Star Therapeutics headquartered?
F-Star Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of F-Star Therapeutics?
F-Star Therapeutics has 88 total employees.
-
What industry is F-Star Therapeutics in?
F-Star Therapeutics’s primary industry is Drug Discovery.
-
Is F-Star Therapeutics a private or public company?
F-Star Therapeutics is a Private company.
-
What is F-Star Therapeutics’s current revenue?
The current revenue for F-Star Therapeutics is .
-
How much funding has F-Star Therapeutics raised over time?
F-Star Therapeutics has raised $57.5M.
-
Who are F-Star Therapeutics’s investors?
Aescap Life Sciences, Atlas Venture, INiTS Universitäres Gründerservice, M Ventures, and MP Healthcare Venture Management are 5 of 11 investors who have invested in F-Star Therapeutics.
-
Who are F-Star Therapeutics’s competitors?
Agios Pharmaceuticals, Adaptimmune Therapeutics, Achaogen, Biosynthema, and Oncorus are some of the 52 competitors of F-Star Therapeutics.
-
When was F-Star Therapeutics acquired?
F-Star Therapeutics was acquired on 02-Apr-2025.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
